Abstract

AbstractBackgroundSeparating Alzheimer’s dementia (AD) from dementia with Lewy bodies (DLB) can be challenging, especially in DLB patients with concomitant AD pathology. It is imperative to distinguish the diseases for optimal patient management. To date, no single MRI feature can accurately separate the two diseases. This study examines whether a linear combination of regional atrophy measures can differentiate cognitively normal (CN), AD, and DLB patients.MethodWe computed volumes of 70 brain regions using an automatic segmentation tool. For each region, we derived age, sex, and head size‐dependent z‐scores. A linear classifier with all brain regions was used to predict if a patient belonged to CN, AD, or DLB. Diagnoses were based on international consensus criteria and CSF‐biomarkers. The classifier was tested in 327 CN (mean age 67±10y, 48%F), 501 AD (70±9y, 49%F), and 99 DLB (69±7y, 15%F) patients from three cohorts (ADNI, PredictND, ADC). The ADC cohort was assessed separately, as almost all DLB patients were from the ADC. In addition, we assessed classification performance in a subgroup of DLB patients with AD‐like CSF (DLB+, n = 57). Performance was evaluated using 10‐fold cross‐validation.ResultPerformance measures for the classifier are summarized in Table 1. The classifier accuracy was assessed in the three‐class classification task and in two‐class classifications where one of the groups was excluded from the analysis. The balanced accuracy in the three‐class classification was 67% for the DLB group and the DLB+ subgroup. For AD vs. DLB, the AUC was 0.77(95% CI:0.70‐0.82), for AD vs. DLB+ AUC was 0.72(0.64‐0.80). The classifier correctly classified CN and AD patients more often than DLB patients (Table 2). Most DLB+ patients were misclassified as AD. The hippocampus was the best single region for distinguishing AD vs. DLB, with an AUC of 0.70(0.64‐0.76).ConclusionThe joint classifier achieved high accuracy in separating AD vs. DLB patients. Although the accuracy was lower, the classifier could distinguish DLB patients with concomitant AD pathology from AD. Next, we will combine different brain regions to discern disease‐specific patterns and add clinical data to the classifier to improve differential diagnostic accuracy for DLB and DLB with concomitant AD pathology.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call